| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2016-02-10 | BlackRock Inc. | CTI BIOPHARMA CORP | 12,693,653 | 4.5% | EDGAR |
| SC 13G | 2016-01-29 | NB Public Equity K/S | CTI BIOPHARMA CORP | 12,666,354 | 5.5% | EDGAR |
| SC 13G | 2016-01-28 | BlackRock Inc. | CTI BIOPHARMA CORP | 11,815,119 | 5.1% | EDGAR |
| SC 13D/A | 2016-01-14 | BIOTECHNOLOGY VALUE FUND L P | CTI BIOPHARMA CORP | 15,592,160 | 5.5% | EDGAR |
| SC 13D/A | 2016-01-11 | BIOTECHNOLOGY VALUE FUND L P | CTI BIOPHARMA CORP | 15,592,160 | 5.5% | EDGAR |
| SC 13D | 2015-12-11 | BIOTECHNOLOGY VALUE FUND L P | CTI BIOPHARMA CORP | 14,897,559 | 5.3% | EDGAR |
| SC 13G/A | 2015-12-10 | BlackRock Inc. | CTI BIOPHARMA CORP | 10,184,243 | 4.4% | EDGAR |
| SC 13G/A | 2015-12-07 | BIOTECHNOLOGY VALUE FUND L P | CTI BIOPHARMA CORP | 14,897,559 | 5.3% | EDGAR |
| SC 13G | 2015-11-10 | FMR LLC | CTI BIOPHARMA CORP | 28,801,722 | 13.9% | EDGAR |
| SC 13G | 2015-10-02 | BIOTECHNOLOGY VALUE FUND L P | CTI BIOPHARMA CORP | 4,875,471 | 2.6% | EDGAR |
| SC 13G/A | 2015-06-08 | EAGLE ASSET MANAGEMENT INC | CTI BIOPHARMA CORP | 972,419 | 0.5% | EDGAR |
| SC 13G/A | 2015-05-01 | BAXTER INTERNATIONAL INC | CTI BIOPHARMA CORP | 15,673,981 | 8.7% | EDGAR |
| SC 13G | 2015-05-01 | Baxalta Inc | CTI BIOPHARMA CORP | 15,673,981 | 8.7% | EDGAR |
| SC 13G/A | 2015-02-13 | FMR LLC | CTI BIOPHARMA CORP | 4,279,150 | 2.4% | EDGAR |
| SC 13G/A | 2015-02-02 | BlackRock Inc. | CTI BIOPHARMA CORP | 9,744,234 | 5.5% | EDGAR |
| SC 13G | 2015-01-07 | EAGLE ASSET MANAGEMENT INC | CTI BIOPHARMA CORP | 12,713,051 | 7.2% | EDGAR |
| SC 13G/A | 2014-02-14 | FMR LLC | CELL THERAPEUTICS INC | 7,134,427 | 5.5% | EDGAR |
| SC 13G | 2014-01-28 | BlackRock Inc. | CELL THERAPEUTICS INC | 8,653,975 | 5.9% | EDGAR |
| SC 13G | 2013-11-25 | BAXTER INTERNATIONAL INC | CELL THERAPEUTICS INC | 15,673,981 | 10.8% | EDGAR |
| SC 13G/A | 2013-02-14 | FMR LLC | CELL THERAPEUTICS INC | 8,036,957 | 8.2% | EDGAR |